Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion
As the landscape grows more competitive, their role will be crucial in determining the success of brands like Farxiga and Jardiance.
- As the landscape grows more competitive, their role will be crucial in determining the success of brands like Farxiga and Jardiance.
- This unique positioning compared to other agents was swiftly recognized by nephrologists, prompting them to express a clear preference for the brand.
- Since the label expansion of Eli Lilly/Boehringer Ingelheim's Jardiance to include CKD, nephrologists have rapidly embraced this drug for both their DKD and non-diabetic CKD patients.
- Several of these agents, including SGLT2 inhibitors and Kerendia, have demonstrated their effectiveness in slowing the progression of CKD.